Detalhe da pesquisa
1.
Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice.
Proc Natl Acad Sci U S A;
118(38)2021 09 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34493582
2.
Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen.
NPJ Vaccines;
8(1): 163, 2023 Oct 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37884538
3.
Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model.
NPJ Vaccines;
8(1): 52, 2023 Apr 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37029167
4.
Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine.
Front Immunol;
13: 976968, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36119058
5.
Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses.
NPJ Vaccines;
6(1): 135, 2021 Nov 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34750396
6.
Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters.
bioRxiv;
2021 Mar 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33688647
7.
Author Correction: Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model.
NPJ Vaccines;
8(1): 86, 2023 Jun 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37277334
8.
Author Correction: Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses.
NPJ Vaccines;
7(1): 3, 2022 Jan 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34987159
9.
Poly(Lactic Acid) Nanoparticles Targeting α5ß1 Integrin as Vaccine Delivery Vehicle, a Prospective Study.
PLoS One;
11(12): e0167663, 2016.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27973577